Abeona Therapeutics Inc. (0H7R.L)
USD 5.88
(-2.0%)
USD 5.88
(-2.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -54.18 Million USD | -36.51% |
| 2022 | -39.69 Million USD | 53.26% |
| 2021 | -84.93 Million USD | -0.83% |
| 2020 | -84.23 Million USD | -10.42% |
| 2019 | -76.28 Million USD | -34.61% |
| 2018 | -56.67 Million USD | -107.44% |
| 2017 | -27.31 Million USD | -24.9% |
| 2016 | -21.87 Million USD | -50.58% |
| 2015 | -14.52 Million USD | 51.01% |
| 2014 | -29.65 Million USD | -2011.86% |
| 2013 | 1.55 Million USD | 112.38% |
| 2012 | -12.53 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 7.4 Million USD | 123.45% |
| 2024 Q1 | -31.57 Million USD | -90.33% |
| 2023 Q3 | -11.83 Million USD | 28.93% |
| 2023 FY | -54.18 Million USD | -36.51% |
| 2023 Q2 | -16.65 Million USD | -82.87% |
| 2023 Q4 | -16.59 Million USD | -40.17% |
| 2023 Q1 | -9.1 Million USD | -708.79% |
| 2022 FY | -39.69 Million USD | 53.26% |
| 2022 Q3 | -9.48 Million USD | -14.33% |
| 2022 Q2 | -8.29 Million USD | 60.1% |
| 2022 Q1 | -20.79 Million USD | 55.46% |
| 2022 Q4 | -1.12 Million USD | 88.13% |
| 2021 Q2 | -15.2 Million USD | 4.97% |
| 2021 Q4 | -46.68 Million USD | -562.73% |
| 2021 Q3 | -7.04 Million USD | 53.68% |
| 2021 Q1 | -16 Million USD | -1.1% |
| 2021 FY | -84.93 Million USD | -0.83% |
| 2020 Q3 | -7.23 Million USD | 44.37% |
| 2020 Q2 | -13.01 Million USD | 72.99% |
| 2020 FY | -84.23 Million USD | -10.42% |
| 2020 Q1 | -48.15 Million USD | -193.1% |
| 2020 Q4 | -15.82 Million USD | -118.71% |
| 2019 Q2 | -23.92 Million USD | -28.94% |
| 2019 Q4 | -16.43 Million USD | 5.42% |
| 2019 Q3 | -17.37 Million USD | 27.39% |
| 2019 FY | -76.28 Million USD | -34.61% |
| 2019 Q1 | -18.55 Million USD | -6.16% |
| 2018 Q1 | -10.53 Million USD | -24.62% |
| 2018 Q3 | -16.41 Million USD | -34.11% |
| 2018 Q4 | -17.47 Million USD | -6.46% |
| 2018 FY | -56.67 Million USD | -107.44% |
| 2018 Q2 | -12.24 Million USD | -16.27% |
| 2017 Q3 | -5.34 Million USD | 35.46% |
| 2017 Q2 | -8.27 Million USD | -57.79% |
| 2017 Q1 | -5.24 Million USD | 25.06% |
| 2017 FY | -27.31 Million USD | -24.9% |
| 2017 Q4 | -8.45 Million USD | -58.15% |
| 2016 Q3 | -2.62 Million USD | 60.85% |
| 2016 FY | -21.87 Million USD | -50.58% |
| 2016 Q4 | -7 Million USD | -166.84% |
| 2016 Q2 | -6.7 Million USD | -20.91% |
| 2016 Q1 | -5.54 Million USD | -136.92% |
| 2015 Q4 | -2.34 Million USD | 61.47% |
| 2015 Q2 | -4.11 Million USD | -105.65% |
| 2015 Q1 | -2 Million USD | 84.16% |
| 2015 FY | -14.52 Million USD | 51.01% |
| 2015 Q3 | -6.07 Million USD | -47.65% |
| 2014 FY | -29.65 Million USD | -2011.86% |
| 2014 Q4 | -12.62 Million USD | -471.62% |
| 2014 Q2 | -13.23 Million USD | -735.42% |
| 2014 Q3 | -2.2 Million USD | 83.31% |
| 2014 Q1 | -1.58 Million USD | 10.56% |
| 2013 FY | 1.55 Million USD | 112.38% |
| 2013 Q1 | 3.35 Million USD | -82.49% |
| 2013 Q2 | 867 Thousand USD | -74.15% |
| 2013 Q3 | -899 Thousand USD | -203.69% |
| 2013 Q4 | -1.77 Million USD | -97.0% |
| 2012 FY | -12.53 Million USD | 0.0% |
| 2012 Q4 | 19.15 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 64.634% |
| Dynavax Technologies Corporation | -6.38 Million USD | -748.145% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 4217.629% |
| Perrigo Company plc | -12.7 Million USD | -326.677% |
| Illumina, Inc. | -1.16 Billion USD | 95.333% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 100.904% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 87.797% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.373% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 103.99% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 50.987% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 101.371% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -35.946% |
| Waters Corporation | 642.23 Million USD | 108.437% |
| Biogen Inc. | 1.16 Billion USD | 104.667% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 78.983% |
| Evolus, Inc. | -61.68 Million USD | 12.154% |
| Adicet Bio, Inc. | -142.65 Million USD | 62.015% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 54.277% |
| bluebird bio, Inc. | -211.91 Million USD | 74.429% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 74.103% |
| FibroGen, Inc. | -284.23 Million USD | 80.935% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 104.37% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -21.489% |
| Homology Medicines, Inc. | -53.74 Million USD | -0.828% |
| Geron Corporation | -184.12 Million USD | 70.57% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 87.691% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 64.252% |
| Myriad Genetics, Inc. | -112 Million USD | 51.618% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 36.914% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 88.739% |
| Zoetis Inc. | 2.34 Billion USD | 102.312% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 106.87% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 132.323% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 101.497% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -28.411% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 85.206% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 80.376% |
| Verastem, Inc. | -87.36 Million USD | 37.977% |
| Nektar Therapeutics | -276.05 Million USD | 80.371% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 77.35% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 38.757% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 89.89% |
| OPKO Health, Inc. | -188.86 Million USD | 71.308% |
| Exelixis, Inc. | 207.76 Million USD | 126.081% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 121.701% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 151.053% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -14.068% |
| uniQure N.V. | -308.47 Million USD | 82.434% |
| Imunon, Inc. | -19.51 Million USD | -177.674% |
| Blueprint Medicines Corporation | -506.98 Million USD | 89.312% |
| Insmed Incorporated | -749.56 Million USD | 92.771% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 119.243% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 84.61% |
| TG Therapeutics, Inc. | 12.67 Million USD | 527.62% |
| Incyte Corporation | 597.59 Million USD | 109.068% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 92.875% |